Recent Updates
Recently added Catalysts

Levosimendan

Phase 3

Coronary Artery Bypass Grafting | Small molecule | Cardiovascular |Tenax Therapeutics, Inc.|Last Updated: Apr 22, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment882
FDA Designations
No designations recorded
Clinical trial landscape

Levosimendan · 3 trials · 8 indications

Phase 3 1Phase 2 2
NCT02025621Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary BypassCoronary Artery Bypass Grafting
COMPLETED882 Analytics
PHASE3COMPLETED
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass GraftingUnlock trial analytics
Study Endpoints
Primary Endpoints
Number of Dual Efficacy Endpoint Events
30 days

The all-cause death at 30 days or use of mechanical assist device (IABP, LVAD or ECMO) following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) through Day 5

Number of Quad Efficacy Endpoint Events
30 days

Composite of all-cause death (at 30 days), or perioperative nonfatal MI \[CK-MB \>10xULN or \>100 ng/mL, CK-MB \>5xULN or 50 ng/mL with new Q wave (\>0.04 seconds wide in two contiguous leads) or new left bundle branch block)\] (through Day 5), or need for renal dialysis (through Day 30), or use of mechanical assist device (IABP, LVAD or ECMO) following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) (through Day 5)

Clinical Safety
Duration of study (for up to 2 years); Assessed at Weeks 3, 6, 12, 24, and 48 and Follow-Up Visit (termination visit).

Number of Adverse Events per Patient Population

Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP) With Bicycle Exercise
Baseline, Week 6

Change from baseline Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise at Week 6

Secondary Endpoints
Duration of Intensive Care Unit/Critical or Coronary Care Unit (ICU/CCU) (Days)
participants will be followed for during the participant's hospital stay up to 30 days
Incidence of Low Cardiac Output Syndrome (LCOS)
5 days
Postoperative Use of Secondary Inotrope
24 hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
LevosimendanEXPERIMENTALlevosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
PlaceboPLACEBO_COMPARATORplacebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
Levosimendan Open-LabelOTHERInitial: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion. Ongoing patients are transitioned to daily oral levosimendan (1mg capsules TID)
Levosimendan 2.5mg/mL Injectable SolutionEXPERIMENTAL0.075 - 0.1µg/kg/min for 24 hrs (weekly)
Matching PlaceboPLACEBO_COMPARATOR0.075 - 0.1µg/kg/min for 24 hrs (weekly)
Interventions
NameTypeDescription
LevosimendanDRUG -
PlaceboDRUGmatching placebo
Matching PlaceboDRUGA sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites60

Inclusion Criteria: * Documented LVEF ≤35% measured by ventriculogram, echocardiogram (ECHO), nuclear scan, or MRI within 60 days before surgery. * Scheduled or urgent 1) CABG surgery, 2)CABG with aortic valve surgery, 3) CABG with mitral valve surgery, or 4) mitral valve surgery with or without ot...

Countries:United StatesCanada
Unlock Eligibility Criteria